GUIDANCE
A multicenter phase II trial of maintenance durvalumab (MEDI4736) and olaparib (AZD2281) after standard 1st line treatment (carboplatin/ cisplatin, etoposide, durvalumab) in HRD positive extensive disease (ED) small-cell lung cancer (SCLC)
II
interventionell
National
Olaparib, Durvalumab
Status: In Rekrutierung
Zeitraum
2024
Zentren
5
5
Keine Zentren gesucht
Patienten
29
20
09.10.2026
Klinische Settings
IIIB, IIIC, IV, IVA, IVB, IVC
2nd line
palliativ
Identifier
AIO-TRK-0124/ass
Uni-Koeln-5159
2024-512373-27-00
Kontakt
Leitung
Prof. Dr. med. Jürgen Wolf
Ansprechpartner*in
Dr. med. Felix John
Telefon +49 221 47839957
E-Mail felix.john@uk-koeln.de